Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 6 August 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Sales of Pillaflon fluoropolymer products for the semiconductor and LCD manufacturing equipment industries have exceeded expectations both in Japan and overseas against a backdrop of the rapid recovery in the semiconductor market, and strong sales are expected to continue. In addition, profit is expected to exceed the previous forecast due to higher capacity utilization accompanying the increase in revenue, among other factors.
| Item | Details |
|---|---|
| Net Sales | ¥83,000 million → ¥90,000 million（+8.4%） |
| Operating profit | ¥20,000 million → ¥23,500 million（+17.5%） |
| Ordinary income | ¥20,400 million → ¥23,500 million（+15.2%） |
| Profit attributable to owners of the parent | ¥14,000 million → ¥16,400 million（+17.1%） |
| Net income per share | 204.13 Yen/sen → 239.05 Yen/sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 6 August 2026 |
| Previous-period results | Revenue ¥59,479 million, operating profit ¥12,107 million, ordinary profit ¥12,946 million, net income attributable to owners of the parent ¥8,941 million, and earnings per share ¥129.40 |
| Reason for the revision | Sales of Pillaflon fluoropolymer products for the semiconductor and LCD manufacturing equipment industries have exceeded expectations both in Japan and overseas against a backdrop of the rapid recovery in the semiconductor market, and strong sales are expected to continue. In addition, profit is expected to exceed the previous forecast due to higher capacity utilization accompanying the increase in revenue, among other factors. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales of Pillaflon fluoropolymer products for the semiconductor and LCD manufacturing equipment industries have exceeded expectations in both Japan and overseas against a backdrop of the rapid recovery in the semiconductor market, and strong sales are expected to continue. In addition, profit is expected to exceed the previous forecast due to higher capacity utilization accompanying the increase in revenue, among other factors.